| Field | Specification |
|---|---|
| Target | |
| Alternative names | Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD antigen CD269; Tnfrsf17; Bcm; Bcma |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of mouse BCMA/Tnfrsf17, which shares 78.9% and 95% amino acid (aa) sequence identity with human and rat BCMA/Tnfrsf17, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes tumor necrosis factor receptor superfamily member 17 (gene Tnfrsf17) in mouse and rat samples and is validated for Western blot, IHC and flow cytometry. The predicted molecular weight is 20.4 kDa, and the supplier reports an observed band at about 30 kDa.
BCMA (TNFRSF17) is a receptor for the cytokines APRIL and BAFF expressed mainly on plasma cells and mature B cells. Its signaling through NF-κB and JNK supports the survival of long-lived plasma cells. BCMA is highly expressed on multiple myeloma cells and is a major target in myeloma research.
| Target | Tumor necrosis factor receptor superfamily member 17 (gene Tnfrsf17; UniProt O88472, mouse) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3 |
| Calculated MW | 20.4 kDa |
| Observed MW | 30 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Mouse, Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Mouse) |
Samples with a confirmed band (WB): mouse RAW264.7 cells, rat plasma, mouse plasma.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): mouse spleen tissue, rat spleen tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): Hepa1–6 cells, RAW264.7 cells.
Immunogen
Synthetic peptide from the N-terminal region of mouse BCMA/Tnfrsf17. Sequence identity with the human and rat orthologs: 78.9% and 95%, respectively.
Reactivity Notes
The supplier lists reactivity with mouse and rat. UniProt places tumor necrosis factor receptor superfamily member 17 in the membrane. Tissue expression noted by UniProt (mouse): Detected in spleen, thymus, bone marrow and heart, and at lower levels in kidney and lung. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
